Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors
Authors:
- Mariia RadaevaMRMariia Radaeva
- Huifang LiHLHuifang Li
- Eric LeBlancELEric LeBlanc
- Kush DalalKDKush Dalal
- Fuqiang BanFBFuqiang Ban
- Fabrice CiesielskiFCFabrice Ciesielski
- Bonny ChowBCBonny Chow
- Helene MorinHMHelene Morin
- Shannon AwreySAShannon Awrey
- Kriti SinghKSKriti Singh
- Paul S. RenniePRPaul S. Rennie
- Nada LallousNLNada Lallous
Open Access
Abstract
The mutation-driven transformation of clinical anti-androgen drugs into agonists of the human androgen receptor (AR) represents a major challenge for the treatment of prostate cancer patients. To address this challenge, we have developed a novel class of inhibitors targeting the DNA-binding domain (DBD) of the receptor, which is distanced from the androgen binding site (ABS) targeted by all conventional anti-AR drugs and prone to resistant mutations. While many members of the developed 4-(4-phenylthiazol-2-yl)morpholine series of AR-DBD inhibitors demonstrated the effective suppression of wild-type AR, a few represented by 4-(4-(3-fluoro-2-methoxyphenyl)thiazol-2-yl)morpholine (VPC14368) exhibited a partial agonistic effect toward the mutated T878A form of the receptor, implying their cross-interaction with the AR ABS. To study the molecular basis of the observed cross-reactivity, we co-crystallized the T878A mutated form of the AR ligand binding domain (LBD) with a bound VPC14368 molecule. Computational modelling revealed that helix 12 of AR undergoes a characteristic shift upon VPC14368 binding causing the agonistic behaviour. Based on the obtained structural data we then designed derivatives of VPC14368 to successfully eliminate the cross-reactivity towards the AR ABS, while maintaining significant anti-AR DBD potency.Keywords
Funding Information
- Canadian Cancer Society (706145, F12-03271)
- Canadian Cancer Society Research Institute (706145, F12-03271)
This publication has 68 references indexed in Scilit:
- TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancerProceedings of the National Academy of Sciences, 2013
- Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate CancerInternational Journal of Molecular Sciences, 2013
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyThe Lancet Oncology, 2012
- Targeting the Binding Function 3 (BF3) Site of the Human Androgen Receptor through Virtual Screening.Journal of Medicinal Chemistry, 2011
- The VSGB 2.0 model: A next generation energy model for high resolution protein structure modelingProteins: Structure, Function, and Bioinformatics, 2011
- Effect of B-ring substitution pattern on binding mode of propionamide selective androgen receptor modulatorsBioorganic & Medicinal Chemistry Letters, 2008
- A surface on the androgen receptor that allosterically regulates coactivator bindingProceedings of the National Academy of Sciences, 2007
- Phasercrystallographic softwareJournal of Applied Crystallography, 2007
- Structural Basis for Accommodation of Nonsteroidal Ligands in the Androgen ReceptorJournal of Biological Chemistry, 2005
- Structural basis for antagonism and resistance of bicalutamide in prostate cancerProceedings of the National Academy of Sciences, 2005